AU1113999A
(en)
*
|
1997-10-21 |
1999-05-10 |
Regents Of The University Of California, The |
Target sequences for synthetic molecules and methods of using same
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
AU782966B2
(en)
|
1999-06-08 |
2005-09-15 |
University Of Iowa Research Foundation, The |
Compounds and methods to enhance RAAV transduction
|
US7122335B1
(en)
|
1999-06-08 |
2006-10-17 |
University Of Iowa Research Foundation |
Compounds and methods to enhance rAAV transduction
|
US6979551B2
(en)
*
|
2000-04-03 |
2005-12-27 |
Rigel Pharmaceuticals, Inc. |
Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
|
US6740495B1
(en)
*
|
2000-04-03 |
2004-05-25 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase assay
|
US7208157B2
(en)
*
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
AU2001295041A1
(en)
|
2000-09-08 |
2002-03-22 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
US8241622B2
(en)
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
US20030077279A1
(en)
*
|
2001-10-24 |
2003-04-24 |
Cedars-Sinai Medical Center |
Methods for treating vascular disease by inhibiting toll-like receptor-4
|
WO2003037926A1
(en)
*
|
2001-11-01 |
2003-05-08 |
The University Of British Columbia |
Diagnosis and treatment of infectious diseases through indel-differentiated proteins
|
US20030148986A1
(en)
*
|
2001-12-17 |
2003-08-07 |
Cedars-Sinai Medical Center |
Methods for treating vascular disease by inhibiting myeloid differentiation factor 88
|
US20050095225A1
(en)
|
2003-03-31 |
2005-05-05 |
Engelhardt John F. |
Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders
|
US20060183889A1
(en)
*
|
2005-01-04 |
2006-08-17 |
Bogoev Roumen A |
Alkyl phosphine detergent products and extraction processes
|
US9512196B2
(en)
|
2008-09-22 |
2016-12-06 |
Cedars-Sinai Medical Center |
Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
|
JP4879314B2
(ja)
*
|
2009-12-07 |
2012-02-22 |
独立行政法人農業生物資源研究所 |
ユビキチン依存型タンパク質分解系を利用した生体内タンパク質分解システム,及びそのシステムを利用したタンパク質の機能解明方法
|
WO2011116401A2
(en)
*
|
2010-03-19 |
2011-09-22 |
Sri International |
Arsenical fluorescent agents and assays
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
WO2012056603A1
(ja)
*
|
2010-10-25 |
2012-05-03 |
パナソニック株式会社 |
キメラ嗅覚受容体を用いてcAMPを産生する方法
|
EP3608317A1
(de)
|
2012-01-12 |
2020-02-12 |
Yale University |
Verbindungen und verfahren für den verstärkten abbau von gezielten proteinen und anderen polypeptiden durch eine e3-ubiquitinligase
|
KR101616603B1
(ko)
*
|
2012-10-11 |
2016-04-28 |
서울대학교산학협력단 |
메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
KR20200052995A
(ko)
|
2015-01-20 |
2020-05-15 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
BR112017019751A2
(pt)
|
2015-03-18 |
2018-05-29 |
Arvinas Inc |
composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
WO2017079267A1
(en)
|
2015-11-02 |
2017-05-11 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
US11702672B2
(en)
|
2016-02-08 |
2023-07-18 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
WO2017155973A1
(en)
|
2016-03-07 |
2017-09-14 |
University Of Iowa Research Foundation |
Aav-mediated expression using a synthetic promoter and enhancer
|
EP3445357B1
(de)
|
2016-04-22 |
2021-05-26 |
Dana-Farber Cancer Institute, Inc. |
Bifunktionale moleküle zum abbau von egfr und verfahren zur verwendung
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
EP3454856A4
(de)
|
2016-05-10 |
2019-12-25 |
C4 Therapeutics, Inc. |
Heterocyclische degronimere für zielproteinabbau
|
GB201610156D0
(en)
|
2016-06-10 |
2016-07-27 |
Otsuka Pharma Co Ltd |
Cliptac compositions
|
US11471462B2
(en)
|
2016-06-27 |
2022-10-18 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
EP3512842B1
(de)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indolderivate als abbauer des östrogenrezeptors
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
DK3660004T3
(da)
|
2016-10-11 |
2023-05-08 |
Arvinas Operations Inc |
Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor
|
KR102570992B1
(ko)
|
2016-11-01 |
2023-08-28 |
아비나스 오퍼레이션스, 인코포레이티드 |
타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
|
KR102173464B1
(ko)
|
2016-12-01 |
2020-11-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
CN110741004B
(zh)
|
2016-12-23 |
2023-10-17 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
EP3559006A4
(de)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
Verbindungen und verfahren zum gezielten abbau von fetalen leberkinasepolypeptiden
|
EP3559002A4
(de)
|
2016-12-23 |
2021-02-17 |
Arvinas Operations, Inc. |
Auf egfr-proteolyse gerichtete chimäre moleküle und zugehörige verfahren zur verwendung
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
EP3573977A4
(de)
|
2017-01-26 |
2020-12-23 |
Arvinas Operations, Inc. |
Modulatoren der östrogenrezeptorproteolyse und zugehörige verfahren zur verwendung
|
CN111386263A
(zh)
|
2017-02-08 |
2020-07-07 |
达纳-法伯癌症研究所有限公司 |
调节嵌合抗原受体
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
|
CN111278815B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
戊二酰亚胺
|
EP3679027A1
(de)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydrobenzimidazolone
|
CN111278816B
(zh)
|
2017-09-04 |
2024-03-15 |
C4医药公司 |
二氢喹啉酮
|
EP3684366A4
(de)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
Crbn-liganden und verwendungen davon
|
IL307995A
(en)
|
2017-09-22 |
2023-12-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
EP3710002A4
(de)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
Degrader und degrone für gezielten proteinabbau
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
IL304055A
(en)
|
2017-12-26 |
2023-08-01 |
Kymera Therapeutics Inc |
IRAK joints and used in them
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
CN111902141A
(zh)
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
JP2021521112A
(ja)
|
2018-04-04 |
2021-08-26 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
タンパク質分解の調節因子および関連する使用方法
|
EP3781156A4
(de)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
Spirocyclische verbindungen
|
EP3578561A1
(de)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiroverbindungen
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
WO2020018935A2
(en)
|
2018-07-19 |
2020-01-23 |
University Of Washington |
De novo design of protein switches
|
WO2020041331A1
(en)
|
2018-08-20 |
2020-02-27 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
JP2022516401A
(ja)
|
2018-11-30 |
2022-02-28 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
US11098025B2
(en)
|
2019-01-30 |
2021-08-24 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
US11547759B2
(en)
|
2019-01-30 |
2023-01-10 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
JP2022540935A
(ja)
|
2019-07-17 |
2022-09-20 |
アルビナス・オペレーションズ・インコーポレイテッド |
タウタンパク質標的化化合物および関連する使用方法
|
EP4076524A4
(de)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
Irak-degrader und verwendungen davon
|
MX2022007576A
(es)
|
2019-12-17 |
2022-09-23 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
US11883393B2
(en)
|
2019-12-19 |
2024-01-30 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
EP4076450A4
(de)
|
2019-12-20 |
2024-01-10 |
C4 Therapeutics Inc |
Isoindolinon- und indazolverbindungen zum abbau von egfr
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
MX2022010952A
(es)
|
2020-03-05 |
2022-10-07 |
C4 Therapeutics Inc |
Compuestos para la degradacion dirigida de brd9.
|
TW202200543A
(zh)
|
2020-03-19 |
2022-01-01 |
美商凱麥拉醫療公司 |
Mdm2降解劑及其用途
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CN116457344A
(zh)
|
2020-08-03 |
2023-07-18 |
凯普托尔治疗学股份有限公司 |
低分子量蛋白质降解剂及其应用
|
TW202237095A
(zh)
|
2020-12-03 |
2022-10-01 |
德商艾斯巴赫生物有限公司 |
Alc1抑制劑及與parpi之協同性
|
WO2022197819A1
(en)
*
|
2021-03-17 |
2022-09-22 |
The Trustees Of Princeton University |
Sunscreens derived from kynurenines and other uv-absorbing oxidized amino acids bound to peptides or polymers
|
BR112023021265A2
(pt)
|
2021-04-16 |
2024-02-27 |
Arvinas Operations Inc |
Moduladores da proteólise de bcl6 e métodos de uso associados
|
WO2022255888A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
AU2022330009A1
(en)
|
2021-08-18 |
2024-01-25 |
Gilead Sciences, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
US11981672B2
(en)
|
2021-09-13 |
2024-05-14 |
Montelino Therapeutics Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
WO2023066881A1
(en)
|
2021-10-18 |
2023-04-27 |
Astrazeneca Ab |
Inhibition of map3k15 for treating and preventing diabetes
|
WO2023213833A1
(en)
|
2022-05-02 |
2023-11-09 |
Eisbach Bio Gmbh |
Use of alc1 inhibitors and synergy with parpi
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|